← Back to Analyst Consensus 
BTAI Buy
BioXcel Therapeutics, Inc.
Current Price —
Implied Upside —
Analysts 7
30-Day Momentum
▲ 0 upgrades / ▼ 0 downgrades / 0 reiterations from 0 firms
Next Earnings
Nov 10, 2026 (14 days)
Rating Timeline
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Apr 2, 2026 | HC Wainwright & Co. | maintain | Buy → Buy | — | 44% |
| Mar 17, 2026 | Rodman & Renshaw | initiate | — → Buy | — | 40% |
| Mar 5, 2026 | HC Wainwright & Co. | maintain | Buy → Buy | — | 44% |
| Sep 15, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $10 | 44% |
| Sep 12, 2025 | Mizuho | maintain | Neutral → Neutral | $4 | 52% |
| Aug 28, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $10 | 44% |
| Aug 19, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $10 | 44% |
| Aug 15, 2025 | HC Wainwright & Co. | maintain | Buy → Buy | $10 | 44% |
| Jul 15, 2025 | LUCID CAPITAL MARKETS | reiterate | Buy → Buy | $66 | 33% |
| Jun 23, 2025 | HC Wainwright & Co. | maintain | Buy → Buy | $8 | 44% |
| Mar 19, 2025 | Rodman & Renshaw | initiate | — → Buy | $65 | 40% |
| Jan 30, 2025 | HC Wainwright & Co. | maintain | Buy → Buy | $3 | 44% |
| Jan 7, 2025 | B of A Securities | downgrade | Buy → Underperform | $0.25 | 53% |
| Jan 6, 2025 | Canaccord Genuity | maintain | Buy → Buy | $5 | 48% |
| Oct 21, 2024 | HC Wainwright & Co. | maintain | Buy → Buy | $5 | 44% |
| Sep 6, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $7 | 44% |
| Aug 30, 2024 | Canaccord Genuity | maintain | Buy → Buy | $7 | 48% |
| Aug 9, 2024 | UBS | maintain | Neutral → Neutral | $1 | 54% |
| Aug 8, 2024 | HC Wainwright & Co. | maintain | Buy → Buy | $7 | 44% |
| Jun 27, 2024 | Canaccord Genuity | maintain | Buy → Buy | $7 | 48% |
| May 10, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $10 | 44% |
| Apr 23, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $10 | 44% |
| Mar 18, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $11 | 44% |
| Mar 14, 2024 | Canaccord Genuity | maintain | Buy → Buy | $7 | 48% |
| Mar 13, 2024 | B of A Securities | maintain | Buy → Buy | $7 | 53% |
| Feb 21, 2024 | UBS | downgrade | Buy → Neutral | $4 | 54% |
| Nov 15, 2023 | HC Wainwright & Co. | reiterate | Buy → Buy | $11 | 44% |
| Oct 31, 2023 | HC Wainwright & Co. | reiterate | Buy → Buy | $11 | 44% |
| Oct 26, 2023 | HC Wainwright & Co. | reiterate | Buy → Buy | $11 | 44% |
| Oct 5, 2023 | Truist Securities | downgrade | Buy → Hold | $0 | 55% |
| Sep 13, 2023 | HC Wainwright & Co. | reiterate | Buy → Buy | $11 | 44% |
| Sep 8, 2023 | HC Wainwright & Co. | reiterate | Buy → Buy | $11 | 44% |
| Aug 28, 2023 | HC Wainwright & Co. | reiterate | Buy → Buy | $11 | 44% |
| Aug 23, 2023 | Mizuho | reiterate | Neutral → Neutral | $4 | 52% |
| Aug 18, 2023 | HC Wainwright & Co. | maintain | Buy → Buy | $11 | 44% |
| Aug 15, 2023 | Goldman Sachs | maintain | Neutral → Neutral | $4 | 54% |
| Aug 15, 2023 | Mizuho | downgrade | Buy → Neutral | $4 | 52% |
| Aug 15, 2023 | Truist Securities | maintain | Buy → Buy | $31 | 55% |
| Aug 15, 2023 | Canaccord Genuity | maintain | Buy → Buy | $20 | 48% |
| Jul 17, 2023 | Guggenheim | downgrade | Buy → Neutral | $0 | 52% |
| Jul 3, 2023 | HC Wainwright & Co. | maintain | Buy → Buy | $60 | 44% |
| Jun 30, 2023 | Mizuho | reiterate | Buy → Buy | $40 | 52% |
| May 30, 2023 | HC Wainwright & Co. | reiterate | Buy → Buy | $66 | 44% |
| May 26, 2023 | Goldman Sachs | maintain | Neutral → Neutral | $25 | 54% |
| May 17, 2023 | HC Wainwright & Co. | reiterate | Buy → Buy | $66 | 44% |
| May 11, 2023 | HC Wainwright & Co. | reiterate | Buy → Buy | $66 | 44% |
| May 10, 2023 | Mizuho | maintain | — → Buy | $40 | 52% |
| May 9, 2023 | Guggenheim | maintain | — → Buy | $46 | 52% |
| Mar 21, 2023 | HC Wainwright & Co. | maintain | — → Buy | $66 | 44% |
| Mar 10, 2023 | Jefferies | downgrade | Buy → Hold | $22 | 52% |
Price Target Trend
Mar 27, 2026 Latest: $18.33 Sep 1, 2026
EPS Estimates
0y —
0q —
+1y —
+1q —
Cross-Platform Signals
No cross-platform signals in the last 90 days